The clinical value of intravesical prostatic protrusion in transurethral resection prostate in primary hospitals

doi:10.3877/cma.j.issn.1674-3253.2020.05.010

Abstract

Abstract:

Objective

To explore the clinical value of intravesical prostatic protrusion (IPP) in primary hospitals.

Methods

A total of 105 patients of benign prostatic hyperplasia (BPH) underwent transurethral resection prostate (TURP) in Longchuan County Hospital of Traditional Chinese Medicine from Mar. 2016 to Mar. 2019. The patients were classified into group IPP<5 mm and group IPP≥5 mm, the differences of the maximal urinary flow (Qmax) and residual urine volume (RUV) and index of international prostate symptom score (IPSS) in two groups were analyzed comparatively.

Results

The average Qmax of patients in IPP≥5 mm group was lower than that in IPP<5 mm group, the difference was statistically significant. The average IPSS and average RUV of patients in IPP≥5 mm group were higher than those in IPP <5 mm group, the difference were statistically significant. There was no significant difference in IPSS, RUV and Qmax between the two groups at 3 months after operation. However, in the group of IPP≥5 mm, the Qmax increased, the residual urine volume decreased, and the IPSS score decreased more significantly, the difference were statistically significant.

Concusion

The clinical symptoms and RUV of BPH were positively correlated with the length of IPP, while the Qmax was negatively correlated with the length of IPP. The curative effect of BPH patients with IPP≥5 mm was more significant. IPP is simple and cheap, and the patient has a high degree of acceptance which is suitable for promotion in primary hospitals.

Key words: Benign prostatic hyperplasia, Intravesical protrusion of prostate, Bladder outlet obstructiona, Prostate resection

Jun Zhang, Chunyan Wei, Wanpeng Huang, Ruodan Liu. The clinical value of intravesical prostatic protrusion in transurethral resection prostate in primary hospitals[J]. Chinese Journal of Endourology(Electronic Edition), 2020, 14(05): 360-363.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2020.05.010

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2020/V14/I05/360

Figures/Tables 3

References 11

[1]	卢智泉，聂绍发. 良性前列腺增生的流行病学研究现状[J].国际泌尿系统杂志, 2007, 27(3): 351.
[2]	刘俊峰，谭朝晖，李三祥, 等. 经尿道双极等离子前列腺剜除术与经尿道双极等离子电切术比较治疗前列腺增生的临床研究[J]. 中国循证医学杂志, 2013, 13(12): 1405-1408.
[3]	Hirayama K, Masui K, Hamada A, et al. Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention[J]. J Urol, 2015, 86(3): 565-569.
[4]	那彦群，叶章群，孙光, 等．中国泌尿外科疾病诊断治疗指南[M]（2014版），人民卫生出版社,北京, 2013.
[5]	Keqin Z, Zhishun X, Jing Z, et al. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement[J]. J Urol, 2007, 70(6): 1096-1099.
[6]	Zheng J, Pan J, Qin Y, et al. Role for intravesical prostatic protrusion in lower urinary tract symptom: a fluidstructural interaction analysis study [J] .BMC Urol, 2015,15:86.
[7]	黄维，刘励，陈光勇, 等. 前列腺突入膀胱距离及逼尿肌厚度与膀胱出口梗阻的关系探讨[J]. 东南国防医药, 2012, 14(5): 435-437.
[8]	Lee LS, Sim HG, Lim KB, et al. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment[J]. Int J Urol，2010, 17(1):69-74.
[9]	张浩，司徒杰，张炎,等.膀胱内前列腺突出程度可作为良性前列腺增生临床进展的高危因素[J/CD].中华腔镜泌尿外科杂志(电子版),2012,6(4):292-295.
[10]	许常杰，曹曙，蒋思雄, 等. 前列腺突入膀胱程度与最大尿流率的关系研究[J]. 大连医科大学学报, 2013, 35(5): 464-467.
[11]	郭雪涛，李从刚，刘和. 良性前列腺增生突入膀胱程度与尿流动力学的临床意义[J]. 现代泌尿外科杂志, 2015, 20(10): 712-714.

组别	例数	年龄(岁)	TPV(ml)	Qmax(ml/s)	IPSS(分)	残余尿量(ml)
IPP<5 mm组	59	71.8±6.9	63±13	9.3±2.7	15.9±3.9	54.2±17.3
IPP≥5 mm组	46	71.5±6.6	67±17	6.8±2.2	21.6±6.5	64.3±15.5
t值		0.19	-1.46	5.01	-5.18	-3.10
P值		0.85	0.15	<0.001	<0.001	0.003

组别	例数	年龄(岁)	TPV(ml)	Qmax(ml/s)	IPSS(分)	残余尿量(ml)
IPP<5 mm组	59	71.8±6.9	63±13	9.3±2.7	15.9±3.9	54.2±17.3
IPP≥5 mm组	46	71.5±6.6	67±17	6.8±2.2	21.6±6.5	64.3±15.5
t值		0.19	-1.46	5.01	-5.18	-3.10
P值		0.85	0.15	<0.001	<0.001	0.003

组别	例数	Qmax(ml/s)	IPSS(分)	残余尿量(ml)
IPP<5 mm组	59	16.6±2.3	5.7±2.1	5.1±2.3
IPP≥5 mm组	46	17.0±1.7	5.5±1.9	5.5±1.8
t值		-1.10	0.49	0.97
P值		0.31	0.63	0.33

组别	例数	Qmax(ml/s)	IPSS(分)	残余尿量(ml)
IPP<5 mm组	59	16.6±2.3	5.7±2.1	5.1±2.3
IPP≥5 mm组	46	17.0±1.7	5.5±1.9	5.5±1.8
t值		-1.10	0.49	0.97
P值		0.31	0.63	0.33

组别	例数	Qmax(ml/s)	IPSS(分)	RUV(ml)
IPP<5 mm组	59	7.3±3.0	10.2±4.4	49.1±17.9
IPP≥5 mm组	46	10.2±2.9	16.1±6.5	58.8±17.4
t值		-4.92	-5.24	-2.80
P值		<0.001	<0.001	0.006

Please choose a citation manager

Content to export